ArticleScientific reports2023

Investigation of enzalutamide, docetaxel, and cabazitaxel resistance in the castration resistant prostate cancer cell line C4 using genome-wide CRISPR/Cas9 screening.

Jakob Haldrup et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.